THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein; and

(b) an injectable hyaluronic acid ester,

wherein said admixture is injectable through the skin of a patient and wherein said admixture

(i) comprises a pore former selected from a liquid pore former or sodium bicarbonate or

(ii) does not include a pore former.

2-13. Cancelled

14. (Previously presented) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein; and

(b) an injectable hyaluronic acid ester,

wherein the hyaluronic acid ester is Hyaff11p65, and wherein the admixture is injectable through the skin of the patient.

15. Cancelled

16. (Previously presented) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) BMP-12; and

(b) an injectable hyaluronic acid ester,

wherein the hyaluronic acid ester is Hyaff11p65, and wherein the admixture is injectable through the skin of the patient.

17-21. Cancelled

22. (Previously presented) The composition of claim 1, wherein the hyaluronic acid ester is at least 50% esterified.

23. (Currently amended) The composition of claim 1 ~~or claim 17~~, wherein the hyaluronic acid ester is at least 60% esterified.

24. (Currently amended) The composition of claim 1 ~~or claim 17~~, wherein the hyaluronic acid is at least 65% esterified.

25. (Currently amended) The composition of claim 1 ~~or claim 17~~, wherein the hyaluronic acid is at least 75% esterified.

26. (Currently amended) The composition of claim 1 ~~or claim 17~~, wherein the hyaluronic acid is at least 80% esterified.

27. (Currently amended) The composition of claim 1 ~~or claim 17~~, wherein the hyaluronic acid is 100% esterified.

28. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-2.

29. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-4.

30. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-5.

31. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-6.

32. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-7.

33. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-8.

34. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-9.

35. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-10.

36. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-11.

37. (Previously presented) The composition of claim 14, wherein the osteogenic protein is BMP-12.

38. (New) The composition of claim 1, wherein the liquid pore former is polyethylene glycol.

39. (New) The composition of claim 1, wherein the hyaluronic acid ester is solubilized in an organic solvent.

40. (New) The composition of claim 1, wherein the hyaluronic acid ester is solubilized in an aqueous buffer.

41. (New) The composition of claim 1, further comprising TCP.

42. (New) The composition of claim 1, wherein the osteogenic protein is selected from the group consisting of BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, and BMP-12.

43. (New) The composition of claim 1, wherein the osteogenic protein is BMP-12.

44. (New) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein; and

(b) an injectable hyaluronic acid ester,

wherein the hyaluronic acid ester is Hyaff11, wherein the admixture is injectable through the skin of the patient, and wherein said admixture

(i) comprises a pore former selected from a liquid pore former or sodium bicarbonate or

(ii) does not include a pore former.

45. (New) The composition of claim 44, wherein the liquid pore former is polyethylene glycol.

46. (New) The composition of claim 44, further comprising TCP.

47. (New) The composition of claim 44, wherein the osteogenic protein is BMP-2.

48. (New) The composition of claim 44, wherein the osteogenic protein is BMP-4.

49. (New) The composition of claim 44, wherein the osteogenic protein is BMP-5.

50. (New) The composition of claim 44, wherein the osteogenic protein is BMP-6.

51. (New) The composition of claim 44, wherein the osteogenic protein is BMP-7.

52. (New) The composition of claim 44, wherein the osteogenic protein is BMP-8.

53. (New) The composition of claim 44, wherein the osteogenic protein is BMP-9.

54. (New) The composition of claim 44, wherein the osteogenic protein is BMP-10.

55. (New) The composition of claim 44, wherein the osteogenic protein is BMP-11.

56. (New) The composition of claim 44, wherein the osteogenic protein is BMP-12.

57. (New) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein; and

(b) an injectable hyaluronic acid ester,

wherein the hyaluronic acid ester is Hyaff11p80, wherein the admixture is injectable through the skin of the patient and wherein said admixture

(i) comprises a pore former selected from a liquid pore former or sodium bicarbonate or

(ii) does not include a pore former.

58. (New) The composition of claim 57, wherein the liquid pore former is polyethylene glycol.

59. (New) The composition of claim 57, further comprising TCP.

60. (New) The composition of claim 57, wherein the osteogenic protein is BMP-2.

61. (New) The composition of claim 57, wherein the osteogenic protein is BMP-4.

62. (New) The composition of claim 57, wherein the osteogenic protein is BMP-5.

63. (New) The composition of claim 57, wherein the osteogenic protein is BMP-6.

64. (New) The composition of claim 57, wherein the osteogenic protein is BMP-7.

65. (New) The composition of claim 57, wherein the osteogenic protein is BMP-8.

66. (New) The composition of claim 57, wherein the osteogenic protein is BMP-9.

67. (New) The composition of claim 57, wherein the osteogenic protein is BMP-10.

68. (New) The composition of claim 57, wherein the osteogenic protein is BMP-11.

69. (New) The composition of claim 57, wherein the osteogenic protein is BMP-12.

70. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein; and

(b) Hyaff11,

wherein the admixture is injectable through the skin of a patient and the Hyaff11 is solubilized in organic solvent.

71. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein;

(b) Hyaff11; and

(c) sodium bicarbonate,

wherein the admixture is injectable through the skin of a patient.

72. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein;

(b) Hyaff11; and

(c) polyethylene glycol,

wherein the admixture is injectable through the skin of a patient.

73. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein;

(b) Hyaff11; and

(c) TCP,

wherein the admixture is injectable through the skin of a patient.

74. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein;

(b) Hyaff11;

(c) sodium bicarbonate; and

(d) TCP,

wherein the admixture is injectable through the skin of a patient.

75. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein;

(b) Hyaff11;

(c) polyethylene glycol; and

(d) TCP,

wherein the admixture is injectable through the skin of a patient.

76. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein; and

(b) Hyaff11p80,

wherein the admixture is injectable through the skin of a patient and the Hyaff11p80 is solubilized in organic solvent.

77. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein; and

(b) Hyaff11p65,

wherein the admixture is injectable through the skin of a patient and the Hyaff11p65 is solubilized in aqueous buffer.

78. (New) A composition for injectable delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) an osteogenic protein;

(b) Hyaff11p65; and

(c) TCP,

wherein the admixture is injectable through the skin of a patient.